プロジェクト研究の結果報告

• 標準治療に不応/不耐となった治癒切除不能大腸がんに対するレゴラフェニブ単剤療法の観察研究
  島田 安博（高知医療センター）、山﨑 健太郎（静岡県立静岡がんセンター）
  2017.1.20　第86回大腸癌研究会
  

英文論文

• Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study.
  Yamamoto Y, Yukami H, Yamaguchi T, Ohori H, Nagasu S, Kagawa Y, Sugimoto N, Sonoda H, Yamazaki K, Takashima A, Okuyama H, Hasegawa H, Kondo C, Baba E, Matsumoto T, Kawamoto Y, Kataoka M, Shindo Y, Ishikawa T, Esaki T, Kito Y, Sato T, Funakoshi T, Yamaguchi T, Shimada Y, Moriwaki T.
  Int J Clin Oncol 2024; 29 (12): 1878-1886
  Link to PubMed
• Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
  Shiroyama M, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Shimada Y, Esaki T, Makiyama A, Moriwaki T.
  Sci Rep 2023; 13 (1): 17931
  Link to PubMed
• Clinical impact of primary tumor location in metastatic colorectal cancer patients under later-line regorafenib or trifluridine/tipiracil treatment.
  Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Negoro Y, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okuyama H, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Moriwaki T.
  Front Oncol 2021; 11: 688709
  Link to PubMed
• Clinical outcomes following trifluridine/tipiracil treatment for patients with metastatic colorectal cancer ineligible for regorafenib treatment.
  Niisato Y, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Shimada Y.
  Anticancer Res 2021; 41(4): 2203-2207
  Link to PubMed
• Survival benefit of crossover administration of regorafenib and trifluridine/tipiracil hydrochloride for patients with metastatic colorectal cancer: exploratory analysis of a Japanese Society for Cancer of the Colon and Rectum multicenter observational study (REGOTAS).
  Chida K, Kotani D, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okita Y, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Shimada Y.
  Front Oncol 2021; 11: 576036
  Link to PubMed
• Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
  Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Tsuji A, Tsuchihashi K, Sakai D, Ueno H, Tamura T, Yamashita K, Shimada Y.
  Int J Clin Oncol 2020; 25(4): 614-621
  Link to PubMed
• Role of predictive value of the modified Glasgow prognostic score for later-line chemotherapy in patients With metastatic colorectal cancer.
  Tsuchihashi K, Ito M, Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Satake H, Suto T, Sugimoto N, Katsumata K, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Okuyama H, Sakai D, Ueno H, Tamura T, Yamashita K, Kishimoto J, Shimada Y, Baba E.
  Clin Colorectal Cancer 2018; 17(4): e687-e697
  Link to PubMed
• Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum multicenter observational study.
  Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, Satake H, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Sugiyama M, Komatsu Y, Okuyama H, Baba E, Sakai D, Watanabe T, Tamura T, Yamashita K, Gosho M, Shimada Y.
  Oncologist 2018; 23(1): 7-15
  Link to PubMed